Patents by Inventor Mark A. Exley
Mark A. Exley has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9907848Abstract: The present invention relates to the discovery that increases in invariant NKT cell (iNKT) number and/or activity can reduce the incidence or severity of metabolic disorders such as obesity and diabetes. The invention accordingly features methods, kits, and compositions for the treatment of such metabolic disorders by administration of a composition capable of increasing iNKT activity.Type: GrantFiled: September 9, 2013Date of Patent: March 6, 2018Assignee: Beth Israel Deaconess Medical Center, Inc.Inventors: Mark A. Exley, Lydia Lynch, Donal O'Shea, Cliona O'Farrelly, Steven P. Balk
-
Publication number: 20150299320Abstract: The invention provides compounds and methods for the ex vivo or in vivo expansion of NK T cells, CD1d-reactive T cells, and J?Q+ T cells, and the modulation of their activities. These compounds and methods have diagnostic and therapeutic applications.Type: ApplicationFiled: September 24, 2014Publication date: October 22, 2015Inventors: Mark A. Exley, Samuel B. Wilson, Steven P. Balk
-
Patent number: 8540999Abstract: The present invention provides nucleic acid sequences coding for the Cryptomeria japonica major pollen allergen Cry j I, Cry j II, Jun s I and Jun v I and fragments or peptides thereof. The present invention also provides purified Cry j I, Cry j II, Jun s I and Jun v I and at least one fragment thereof produced in a host cell transformed with a nucleic acid sequence coding for Cry j I, Cry j II, Jun s I and Jun v I or at least one fragment thereof, and fragments of Cry j I, Cry j II, Jun s I or Jun v I or at least one fragment thereof, and fragments of Cry j I, Cry j II, Jun s I or Jun v I prepared synthetically. Cry j I, Cry j II, Jun s I and Jun v I and fragments thereof are useful for diagnosing, treating, and preventing Japanese cedar pollinosis. The present invention also provides isolated peptides of Cry j I and Cry j II. Peptides within the scope of the invention comprise at least one T cell epitope, or preferably at least two T cell epitopes of Cry j I or Cry j II.Type: GrantFiled: August 30, 2004Date of Patent: September 24, 2013Assignee: Merck Patent GmbHInventors: Irwin J. Griffith, Joanne Pollock, Julian F. Bond, Richard D. Garman, Mei-Chang Kuo, Stephen P. Powers, Mark A. Exley, Xian Chen, Ze'ev Shaked
-
Publication number: 20120258040Abstract: The invention provides compounds and methods for the ex vivo or in vivo expansion of NK T cells, CD1d-reactive T cells, and J?Q+ T cells, and the modulation of their activities. These compounds and methods have diagnostic and therapeutic applications.Type: ApplicationFiled: March 19, 2012Publication date: October 11, 2012Applicants: Beth Israel Deaconess Medical Center, Inc, The General Hospital Corporation, Dana Farber Cancer InstituteInventors: Mark A. Exley, Samuel B. Wilson, Steven P. Balk
-
Publication number: 20120164138Abstract: The invention provides methods for the administration of an anti-CD1 antibody for the treatment or prevention of a variety of disorders, such as autoimmune disease, viral infection, bacterial infection, parasitic infection, infection by a eukaryotic pathogen, allergy, asthma, inflammatory condition, graft versus host disease, graft rejection, immunodeficiency disease, spontaneous abortion, pregnancy, and cancer.Type: ApplicationFiled: December 6, 2011Publication date: June 28, 2012Applicant: Beth Israel Deaconess Medical CenterInventors: Mark A. Exley, Steven P. Balk, Simon C. Yue
-
Patent number: 8138314Abstract: The invention provides compounds and methods for the ex vivo or in vivo expansion of NK T cells, CD1d-reactive T cells, and J?Q+ T cells, and the modulation of their activities. These compounds and methods have diagnostic and therapeutic applications.Type: GrantFiled: October 2, 2006Date of Patent: March 20, 2012Assignees: Beth Israel Deaconess Medical Center, Inc., Dana-Farber Cancer Institute, The General Hospital CorporationInventors: Mark A. Exley, Samuel B. Wilson, Steven P. Balk
-
Patent number: 8084020Abstract: The invention provides methods for the administration of an anti-CD 1 antibody for the treatment or prevention of a variety of disorders, such as autoimmune disease, viral infection, bacterial infection, parasitic infection, infection by a eukaryotic pathogen, allergy, asthma, inflammatory condition, graft versus host disease, graft rejection, immunodeficiency disease, spontaneous abortion, pregnancy, and cancer.Type: GrantFiled: May 1, 2003Date of Patent: December 27, 2011Assignee: Beth Israel Deaconess Medical CenterInventors: Mark A. Exley, Steven P. Balk, Simon C. Yue
-
Publication number: 20100209449Abstract: Hapten-carrier conjugates capable of eliciting anti-hapten antibodies in vivo by administering, in a therapeutic composition, are disclosed. Methods of preparing said conjugates and therapeutic compositions are also disclosed. Where the hapten is a drug of abuse, a therapeutic composition containing the hapten-carrier conjugate is particularly useful in the treatment of drug addiction, more particularly, cocaine addiction. Passive immunization using antibodies raised against conjugates of the instant invention is also disclosed. The therapeutic composition is suitable for co-therapy with other conventional drugs.Type: ApplicationFiled: April 23, 2010Publication date: August 19, 2010Inventors: Philip A. Swain, Victoria C. Schad, Julia L. Greenstein, Mark A. Exley, Barbara S. Fox, Stephen P. Powers, Malcolm L. Gefter
-
Publication number: 20100105672Abstract: Hapten-carrier conjugates capable of eliciting anti-hapten antibodies in vivo by administering, in a therapeutic composition, are disclosed. Methods of preparing said conjugates and therapeutic compositions are also disclosed. Where the hapten is a drug of abuse, a therapeutic composition containing the hapten-carrier conjugate is particularly useful in the treatment of drug addiction, more particularly, cocaine addiction. Passive immunization using antibodies raised against conjugates of the instant invention is also disclosed. The therapeutic composition is suitable for co-therapy with other conventional drugs.Type: ApplicationFiled: August 3, 2009Publication date: April 29, 2010Inventors: Philip A. Swain, Victoria C. Schad, Julia L. Greenstein, Mark A. Exley, Barbara S. Fox, Stephen P. Powers
-
Publication number: 20100068222Abstract: Hapten-carrier conjugates capable of eliciting anti-hapten antibodies in vivo by administering, in a therapeutic composition, are disclosed. Methods of preparing said conjugates and therapeutic compositions are also disclosed. Where the hapten is a drug of abuse, a therapeutic composition containing the hapten-carrier conjugate is particularly useful in the treatment of drug addiction, more particularly, cocaine addiction. Passive immunization using antibodies raised against conjugates of the instant invention is also disclosed. The therapeutic composition is suitable for co-therapy with other conventional drugs.Type: ApplicationFiled: August 3, 2009Publication date: March 18, 2010Inventors: Philip A. Swain, Victoria C. Schad, Julia L. Greenstein, Mark A. Exley, Barbara S. Fox, Stephen P. Powers
-
Publication number: 20090068210Abstract: Methods and compositions for treating, preventing and/or managing various hematological malignancies are disclosed. Specific methods and compositions relate to use of tumor cells engineered to express antigen presenting molecules which present antigens recognized by iNKT cells and eliciting antitumor immune response from iNKT cells using such tumor cells, optionally in combination with an immunomodulatory compound.Type: ApplicationFiled: July 8, 2008Publication date: March 12, 2009Inventors: Nikhil C. Munshi, Weihua Song, Mark A. Exley
-
Patent number: 6982326Abstract: The present invention provides nucleic acid sequences coding for the Cryptomeria japonica major pollen allergen Cry j I, Cry j II, Jun s I and Jun v I and fragments or peptides thereof. The present invention also provides purified Cry j I, Cry j II, Jun s I and Jun v I and at least one fragment thereof produced in a host cell transformed with a nucleic acid sequence coding for Cry j I, Cry j II, Jun s I and Jun v I or at least one fragment thereof, and fragments of Cry j I, Cry j II, Jun s I or Jun v I or at least one fragment thereof, and fragments of Cry j I, Cry j II, Jun s I or Jun v I prepared synthetically. Cry j I, Cry j II, Jun s I and Jun v I and fragments thereof are useful for diagnosing, treating, and preventing Japanese cedar pollinosis. The present invention also provides isolated peptides of Cry j I and Cry j II. Peptides within the scope of the invention comprise at least one T cell epitope, or preferably at least two T cell epitopes of Cry j I or Cry j II.Type: GrantFiled: January 29, 1999Date of Patent: January 3, 2006Assignee: ImmuLogic Pharmaceutical CorporationInventors: Irwin J. Griffith, Joanne Pollock, Julian F. Bond, Richard D. Garman, Mei-chang Kuo, Stephen P. Powers, Mark A. Exley, Xian Chen, Ze'ev Shaked
-
Publication number: 20030069400Abstract: Hapten-carrier conjugates capable of eliciting anti-hapten antibodies in vivo by administering, in a therapeutic composition, are disclosed. Methods of preparing said conjugates and therapeutic compositions are also disclosed. Where the hapten is a drug of abuse, a therapeutic composition containing the hapten-carrier conjugate is particularly useful in the treatment of drug addiction, more particularly, cocaine addiction. Passive immunization using antibodies raised against conjugates of the instant invention is also disclosed. The therapeutic composition is suitable for co-therapy with other conventional drugs.Type: ApplicationFiled: April 1, 2002Publication date: April 10, 2003Applicant: Xenova Research LimitedInventors: Philip A. Swain, Victoria C. Schad, Julia L. Greenstein, Mark A. Exley, Barbara S. Fox, Stephen P. Powers, Malcolm L. Gefter
-
Publication number: 20020164331Abstract: The invention provides compounds and methods for the ex vivo or in vivo expansion of NK T cells, CD1d-reactive T cells, and J&agr;Q+ T cells, and the modulation of their activities. These compounds and methods have diagnostic and therapeutic applications.Type: ApplicationFiled: June 19, 2001Publication date: November 7, 2002Inventors: Mark A. Exley, Samuel B. Wilson, Steven P. Balk
-
Publication number: 20020032316Abstract: Hapten-carrier conjugates capable of eliciting anti-hapten antibodies in vivo by administering, in a therapeutic composition, are disclosed. Methods of preparing said conjugates and therapeutic compositions are also disclosed. Where the hapten is a drug of abuse, a therapeutic composition containing the hapten-carrier conjugate is particularly useful in the treatment of drug addiction, more particularly, cocaine addiction. Passive immunization using antibodies raised against conjugates of the instant invention is also disclosed. The therapeutic composition is suitable for co-therapy with other conventional drugs.Type: ApplicationFiled: June 14, 2001Publication date: March 14, 2002Applicant: Cantab Pharmaceuticals Research LimitedInventors: Philip A. Swain, Victoria C. Schad, Julia L. Greenstein, Mark A. Exley, Barbara S. Fox, Stephen P. Powers, Malcolm L. Gefter
-
Patent number: 6090386Abstract: The present invention provides nucleic acid sequences coding for the Cryptomeria japonica major pollen allergen Cry j I, Cry j II, Jun s I and Jun v I and fragments or peptides thereof. The present invention also provides purified Cry j I, Cry j II, Jun s I and Jun v I and at least one fragment thereof produced in a host cell transformed with a nucleic acid sequence coding for Cry j I, Cry j II, Jun s I and Jun v I or at least one fragment thereof, and fragments of Cry j I, Cry j II, Jun s I or Jun v I or at least one fragment thereof, and fragments of Cry j I, Cry j II, Jun s I or Jun v I prepared synthetically. Cry j I, Cry j II, Jun s I and Jun v I and fragments thereof are useful for diagnosing, treating, and preventing Japanese cedar pollinosis. The present invention also provides isolated peptides of Cry j I and Cry j II. Peptides within the scope of the invention comprise at least one T cell epitope, or preferably at least two T cell epitopes of Cry j I or Cry j II.Type: GrantFiled: June 6, 1995Date of Patent: July 18, 2000Inventors: Irwin J. Griffith, Joanne Pollock, Julian F. Bond, Richard D. Garman, Mei-chang Kuo, Stephen P. Powers, Mark A. Exley, Xian Chen, Ze'ev Shaked
-
Patent number: 6054127Abstract: Hapten-carrier conjugates capable of eliciting anti-hapten antibodies in vivo are disclosed. Methods of preparing the hapten-carrier conjugates and therapeutic compositions are also disclosed. Where the hapten is a drug of abuse, a therapeutic composition containing the hapten-carrier conjugate is particularly useful in the treatment of drug addiction, more particularly, cocaine addiction. Passive immunization using antibodies raised against conjugates of the instant invention is also disclosed. The therapeutic composition is suitable for co-therapy with other conventional drugs.Type: GrantFiled: June 27, 1997Date of Patent: April 25, 2000Assignee: Immulogic Pharmaceutical CorporationInventors: Philip A. Swain, Victoria C. Schad, Julia L. Greenstein, Mark A. Exley, Barbara S. Fox, Stephen P. Powers, Malcolm L. Gefter, Thomas J. Briner
-
Patent number: 5876727Abstract: Hapten-carrier conjugates capable of eliciting anti-hapten antibodies in vivo are disclosed. Methods of preparing the hapten-carrier conjugates and therapeutic compositions are also disclosed. Where the hapten is a drug of abuse, a therapeutic composition containing the hapten-carrier conjugate is particularly useful in the treatment of drug addiction, more particularly, cocaine addiction. Passive immunization using antibodies raised against conjugates of the instant invention is also disclosed. The therapeutic composition is suitable for co-therapy with other conventional drugs.Type: GrantFiled: September 30, 1996Date of Patent: March 2, 1999Assignee: ImmuLogic Pharmaceutical CorporationInventors: Philip A. Swain, Victoria C. Schad, Julia L. Greenstein, Mark A. Exley, Barbara S. Fox, Stephen P. Powers, Malcolm L. Gefter
-
Patent number: 5760184Abstract: Hapten-carrier conjugates capable of eliciting anti-hapten antibodies in vivo are disclosed. Methods of preparing the hapten-carrier conjugates and therapeutic compositions are also disclosed. Where the hapten is a drug of abuse, a therapeutic composition containing the hapten-carrier conjugate is particularly useful in the treatment of drug addiction, more particularly, cocaine addiction. Passive immunization using antibodies raised against conjugates of the instant invention is also disclosed. The therapeutic composition is suitable for co-therapy with other conventional drugs.Type: GrantFiled: November 28, 1995Date of Patent: June 2, 1998Assignee: ImmuLogic, Inc.Inventors: Philip A. Swain, Victoria C. Schad, Julia L. Greenstein, Mark A. Exley, Barbara S. Fox, Stephen P. Powers, Malcolm L. Gefter, Thomas J. Briner